Calcium-sensing Receptor Agonist Drug Class List

Drugs in Drug Class: Calcium-sensing Receptor Agonist

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-003	Mar 8, 2004		DISCN	Yes	No			Y
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-003	Mar 8, 2004		DISCN	Yes	No			Y
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-001	Mar 8, 2004		DISCN	Yes	No			Y
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-001	Mar 8, 2004		DISCN	Yes	No			Y
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-002	Mar 8, 2004		DISCN	Yes	No			Y
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-002	Mar 8, 2004		DISCN	Yes	No			Y

Calcium-Sensing Receptor (CaSR) Agonists: Market Dynamics and Patent Landscape

Last updated: April 23, 2026

What is the current market shape for CaSR agonist drugs?

Calcium-sensing receptor agonists are positioned around disorders driven by impaired calcium homeostasis, especially:

• Chronic kidney disease-mineral and bone disorder (CKD-MBD) and related secondary hyperparathyroidism (sHPT).
• Hypercalcemia syndromes where CaSR activation can reduce parathyroid hormone (PTH) signaling.
• Hypoparathyroidism in select cases through downstream regulation of calcium-PTH feedback.

Market pull comes from payer logic: fewer injections, lower monitoring burden

Across endocrine and mineral metabolism categories, buyers value:

• Stable dosing with predictable calcium/PTH control.
• Lower monitoring intensity compared with older standard-of-care options.
• Reduced adverse event load tied to calcium excursions (hypercalcemia, nephrolithiasis risk).

Where revenue concentration sits today

The CaSR-agonist category has historically been dominated by a small number of assets:

• Cinacalcet and etelcalcetide are established in sHPT (calcimimetic class; cinacalcet is oral).
• CaSR agonists outside the calcimimetic standard tend to compete on differentiation: dosing convenience, faster titration, and safety in specific renal and mineral pathways.

In practice, the patent landscape and clinical data dictate which products can defend share through exclusivity extensions versus which entrants must compete on label-specific evidence.

---

Which molecules define the CaSR agonist competitive set?

A practical competitive map for CaSR agonist-related IP and market access looks like this:

Molecule / Asset	Typical Positioning	Route	IP center of gravity (high level)
Cinacalcet	sHPT in CKD; chronic management	Oral	Composition + use + process patents historically; generics dominate post-expiry markets
Etelcalcetide	sHPT in dialysis patients; injectable option	IV/SC (formulation-dependent)	Product/formulation and method-of-use estates; lifecycle management matters
Direct CaSR agonists outside classic calcimimetics	Endocrine and mineral balance disorders	Varies	Novel chemical entity (NCE) and delivery platform often determine defensibility

The business reality: if a new CaSR agonist is not differentiated on clinical outcomes, it competes primarily on access, dosing, and tolerability, which quickly compress margins unless IP is strong.

---

What are the main market dynamics shaping adoption?

1) Dialysis and CKD care pathways standardize prescribing

sHPT in CKD is treated within structured care pathways, where switching and reimbursement depend on:

• Evidence in dialysis populations
• Protocol acceptance in nephrology centers
• Safety performance in real-world calcium and PTH control

2) Drug affordability and payer pressure

When oral branded therapy faces generic pressure, market share erosion accelerates. Buyers also compare total cost of care:

• Drug cost
• Lab frequency
• Hospitalizations related to mineral/bone complications

3) Safety tolerance is a switching lever

CaSR agonism can drive hypocalcemia risk. Adoption tends to favor:

• Agents with more manageable titration
• Clear calcium monitoring workflows
• Lower rates of clinically meaningful adverse events

---

How does the patent landscape determine who can enter and who can defend share?

IP typology in CaSR agonists

CaSR-targeted products typically rely on four layers of exclusivity:

1. Primary composition-of-matter (MoA-level) patents for the active ingredient(s).
2. Pharmaceutical composition and formulation patents (salts, polymorphs, particle size, controlled release, stability).
3. Method-of-use patents tied to patient subgroups, dosing regimens, and monitoring approaches.
4. Regulatory exclusivity (where applicable) plus patent term adjustments/extensions and jurisdiction-specific mechanisms.

In heavily contested markets, lifecycle value often shifts from the core MoA patent to downstream formulation or use patents that can survive longer.

---

What does the patent landscape look like by claim type?

Composition-of-matter: long runway, but crowded by generics

For older calcimimetic incumbents, the composition portfolio largely determines:

• Whether generics can launch
• Whether “skinny labeling” or non-infringing formulations can be engineered

For newer entrants, composition-of-matter patents remain the strongest barrier, but only if they cover:

• The exact stereochemistry and salt form used in the commercial product
• Analog series and variants likely to be used in future improvements

Formulation: the highest chance to extend exclusivity in practice

Formulation patents often determine:

• Patent life relative to market uptake timing
• Coverage for the specific dosage form (solution vs suspension; concentration; excipients)
• Stability claims that can restrict manufacturing workarounds

Method-of-use: the main lever for label expansion or defense

Use patents are often tailored to:

• Specific CKD stages or dialysis modalities
• PTH targets and monitoring schedules
• Starting dose and titration schema that reduce hypocalcemia events

This matters because method-of-use coverage can maintain differentiation even when general MoA coverage erodes.

---

Which jurisdictions and mechanisms drive enforceability for CaSR agonists?

United States: exclusivity + Orange Book strategy

In the US, enforceability and market entry dynamics typically hinge on:

• FDA Orange Book listing coverage (active ingredient and approved drug product patents)
• Hatch-Waxman framework for ANDA/505(b)(2) challengers
• Use of CFR and FDA labeling alignment with patent claim scope

European Union: unitary practice differs but validity and scope still decide value

In Europe, decision points include:

• Validity in each member state (national litigation)
• Whether EP equivalents have broad or narrow claim construction
• Whether SPCs exist for the key active ingredient, and how they cover specific dosage forms

---

What are the practical implications for investment and R&D?

1) IP defensibility is not just “number of patents”

For CaSR agonists, the defensibility equation is:

• Claim coverage breadth around the marketed salt/form and dosage form
• Likelihood of successful enforcement before key generic entry windows
• Whether method-of-use claims map tightly to the label strategy

2) Product strategy should assume generics and design-around

R&D programs that rely only on broad MoA claims face fast erosion. Winning programs build a second wall:

• Formulation and delivery patents that lock in manufacturing and stability characteristics
• Use patents that connect to clinical monitoring routines and endpoints that payers demand

3) Target selection should map to claim eligibility

Patient populations matter because method-of-use claims must be:

• Legally enforceable in target jurisdictions
• Aligned with clinical evidence packages for label expansion
• Compatible with payer preferences for measurable outcomes

---

Key Takeaways

• CaSR agonists compete in a payer-driven endocrine workflow where adoption depends on calcium/PTH control and low clinical burden.
• Patent value in this class concentrates in formulation and method-of-use estates once composition-of-matter coverage becomes vulnerable.
• US enforceability typically tracks tightly to FDA Orange Book listing strategy and Hatch-Waxman exposure; EU value hinges on claim scope and validity plus SPC coverage mechanics.
• The highest-probability defensibility strategy pairs a strong core patent with downstream patents that cover the exact marketed dosage form and label-relevant dosing/titration approach.

---

FAQs

1) What drives differentiation in CaSR agonists when the MoA is shared?

Label-specific dosing, titration scheme, monitoring workflow, and safety profile (especially hypocalcemia management) tied to enforceable method-of-use and formulation patents.

2) Why do formulation patents matter so much for CaSR agonists?

They protect the specific drug product configuration (salt/form, stability, excipients, delivery characteristics), which can block or delay generic and “design-around” manufacturing.

3) Are method-of-use patents a realistic defense in the US?

Yes when they are aligned to approved labeling, properly listed for Orange Book coverage where applicable, and supported by claim scope that matches real clinical use.

4) How does generic entry typically impact the revenue curve for older CaSR drugs?

Once composition-of-matter coverage erodes and launch barriers fall, pricing pressure accelerates, and share shifts based on payer switching policies and real-world safety performance.

5) What patent claim types are most likely to support label expansion?

Those that map to clinical endpoints and dosing regimens in specific CKD/dialysis subpopulations, with monitoring schedules that are defensible and practical for routine care.

---

References

[1] FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Database). https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency (EMA). Summary of Product Characteristics and related regulatory documents. (Database). https://www.ema.europa.eu/
[3] FDA. Hatch-Waxman Act: Guidance and regulatory framework for ANDA/505(b)(2). (Regulatory resources). https://www.fda.gov/
[4] World Health Organization (WHO). ATC classification system and therapeutic subgrouping (Mineral metabolism agents and relevant endocrine categories). https://www.who.int/teams/health-product-policy-standards/standards-and-specifications/atc-index